Spots Global Cancer Trial Database for amrubicin
Every month we try and update this database with for amrubicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | NCT00375193 | Small Cell Lung... | Amrubicin | 18 Years - | Celgene | |
| A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | NCT01364727 | Thymoma Thymus Cancer Thymic Carcinom... | Amrubicin | 18 Years - | Stanford University | |
| Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | NCT01331824 | Bladder Cancer | Amrubicin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | NCT00319969 | Small Cell Lung... | Amrubicin Topotecan | 18 Years - | Celgene | |
| Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | NCT02481830 | Lung Cancer | Nivolumab Topotecan Amrubicin | 18 Years - | Bristol-Myers Squibb | |
| Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT01355705 | Multiple Myelom... | Amrubicin Lenalidomide Dexamethasone Aspirin Pegfilgrastim | 18 Years - | Stanford University | |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | NCT05740566 | Small Cell Lung... | Tarlatamab Lurbinectedin Topotecan Amrubicin | 18 Years - | Amgen | |
| A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors. | NCT00915083 | Advanced Solid ... | Amrubicin | 18 Years - 65 Years | Celgene | |
| AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | NCT00547651 | Small Cell Lung... | Amrubicin Topotecan | 18 Years - | Celgene | |
| Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma | NCT01259375 | Soft Tissue Sar... | Amrubicin | 18 Years - | University of Utah | |
| A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer | NCT01076504 | Extensive-Stage... | Amrubicin Carboplatin Pegfilgrastim | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | NCT06203210 | Small Cell Lung... | Ifinatamab deru... Topotecan Amrubicin Lurbinectedin | 18 Years - | Daiichi Sankyo | |
| Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | NCT00375193 | Small Cell Lung... | Amrubicin | 18 Years - | Celgene | |
| Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | NCT00319969 | Small Cell Lung... | Amrubicin Topotecan | 18 Years - | Celgene | |
| Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | NCT00388960 | Small Cell Lung... | Amrubicin Cisplatin Etoposide | 18 Years - | Celgene | |
| Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | NCT01033032 | Metastatic Brea... | Amrubicin | 18 Years - | SCRI Development Innovations, LLC | |
| A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer | NCT01076504 | Extensive-Stage... | Amrubicin Carboplatin Pegfilgrastim | 18 Years - | SCRI Development Innovations, LLC | |
| Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | NCT01355705 | Multiple Myelom... | Amrubicin Lenalidomide Dexamethasone Aspirin Pegfilgrastim | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
